Literature DB >> 6965618

Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass.

G C Davies, M Sobel, E W Salzman.   

Abstract

Patients who underwent operations in which cardiopulmonary bypass was used had elevations of plasma fibrinopeptide A which did not return to normal during bypass despite conventional heparin anticoagulation, suggesting inadequate heparin dosage and continued thrombin activity during the operation. Patients who underwent aortocoronary artery grafting had high plasma thromboxane B2 levels and a rapid fall in platelet count at the onset of extracorporeal circulation. Thromboxane elevations were less marked in patients who underwent valve replacement. Platelet aggregation and coronary artery constriction secondary to thromboxane production may contribute to the morbidity of cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965618     DOI: 10.1161/01.cir.61.4.808

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target.

Authors:  Reza Aghamohammadzadeh; Sarah Withers; Fiona Lynch; Adam Greenstein; R Malik; Anthony Heagerty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Comparison of the vasorelaxant effect of nitroprusside and nitroglycerin in the human radial artery in vitro.

Authors:  G W He; C Q Yang
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

3.  Impaired contractile response of human peripheral arterioles to thromboxane A-2 after cardiopulmonary bypass.

Authors:  Jun Feng; Yuhong Liu; Arun K Singh; Nikola Dobrilovic; William C Feng; Louis M Chu; Michael P Robich; Kamal R Khabbaz; Frank W Sellke
Journal:  Surgery       Date:  2011-08       Impact factor: 3.982

4.  The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement.

Authors:  David Machin; Philip Devine
Journal:  J Extra Corpor Technol       Date:  2005-09

5.  Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery.

Authors:  G W He; C Q Yang
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

6.  The protective effect of thromboxane A2 synthetase inhibitor against ischemic liver injury.

Authors:  H Isozaki; K Okajima; H Hara; M Kobayashi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery.

Authors:  H Nakamura; D K Kim; D M Philbin; M B Peterson; F Debros; G Koski; J V Bonventre
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 8.  Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation.

Authors:  A R Webb; M G Mythen; D Jacobson; I J Mackie
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.